| Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 JG Doench, N Fusi, M Sullender, M Hegde, EW Vaimberg, KF Donovan, ... Nature biotechnology 34 (2), 184-191, 2016 | 3751 | 2016 |
| FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress Z Tothova, R Kollipara, BJ Huntly, BH Lee, DH Castrillon, DE Cullen, ... Cell 128 (2), 325-339, 2007 | 1779 | 2007 |
| Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation JG Doench, E Hartenian, DB Graham, Z Tothova, M Hegde, I Smith, ... Nature biotechnology 32 (12), 1262-1267, 2014 | 1741 | 2014 |
| FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis JH Paik, R Kollipara, G Chu, H Ji, Y Xiao, Z Ding, L Miao, Z Tothova, ... Cell 128 (2), 309-323, 2007 | 1185 | 2007 |
| The retinoblastoma binding protein RBP2 is an H3K4 demethylase RJ Klose, Q Yan, Z Tothova, K Yamane, H Erdjument-Bromage, P Tempst, ... Cell 128 (5), 889-900, 2007 | 496 | 2007 |
| The telomerase reverse transcriptase regulates chromatin state and DNA damage responses K Masutomi, R Possemato, JMY Wong, JL Currier, Z Tothova, JB Manola, ... Proceedings of the national academy of sciences 102 (23), 8222-8227, 2005 | 492 | 2005 |
| FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system Z Tothova, DG Gilliland Cell stem cell 1 (2), 140-152, 2007 | 346 | 2007 |
| AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias SM Sykes, SW Lane, L Bullinger, D Kalaitzidis, R Yusuf, B Saez, F Ferraro, ... Cell 146 (5), 697-708, 2011 | 299 | 2011 |
| Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation S Elf, NS Abdelfattah, E Chen, J Perales-Patón, EA Rosen, A Ko, ... Cancer discovery 6 (4), 368-381, 2016 | 266 | 2016 |
| FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia BH Lee, Z Tothova, RL Levine, K Anderson, N Buza-Vidas, DE Cullen, ... Cancer cell 12 (4), 367-380, 2007 | 248 | 2007 |
| Core circadian clock genes regulate leukemia stem cells in AML RV Puram, MS Kowalczyk, CG de Boer, RK Schneider, PG Miller, ... Cell 165 (2), 303-316, 2016 | 228 | 2016 |
| mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion JY Lee, D Nakada, OH Yilmaz, Z Tothova, NM Joseph, MS Lim, ... Cell stem cell 7 (5), 593-605, 2010 | 219 | 2010 |
| NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a TL Gu, Z Tothova, B Scheijen, JD Griffin, DG Gilliland, DW Sternberg Blood 103 (12), 4622-4629, 2004 | 142 | 2004 |
| Niche-based screening identifies small-molecule inhibitors of leukemia stem cells KA Hartwell, PG Miller, S Mukherjee, AR Kahn, AL Stewart, DJ Logan, ... Nature chemical biology 9 (12), 840-848, 2013 | 133 | 2013 |
| Hemophagocytic syndrome and critical illness: new insights into diagnosis and management Z Tothova, N Berliner Journal of intensive care medicine 30 (7), 401-412, 2015 | 124 | 2015 |
| Multiplex CRISPR/Cas9-based genome editing in human hematopoietic stem cells models clonal hematopoiesis and myeloid neoplasia Z Tothova, JM Krill-Burger, KD Popova, CC Landers, QL Sievers, ... Cell Stem Cell 21 (4), 547-555. e8, 2017 | 93 | 2017 |
| Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors Z Tothova, AJ Wagner Current Opinion in Oncology 24 (4), 409-413, 2012 | 88 | 2012 |
| Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification MG Cornejo, V Mabialah, SM Sykes, T Khandan, C Lo Celso, CK Lopez, ... Blood, The Journal of the American Society of Hematology 118 (5), 1264-1273, 2011 | 76 | 2011 |
| Intergenerational epigenetic inheritance of cancer susceptibility in mammals BJ Lesch, Z Tothova, EA Morgan, Z Liao, RT Bronson, BL Ebert, DC Page Elife 8, e39380, 2019 | 55 | 2019 |
| Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov. 2016; 6: 368–381. doi: 10.1158/2159-8290 S Elf, NS Abdelfattah, E Chen, J Perales-Patón, EA Rosen, A Ko, ... Go to original source... Go to PubMed, 2018 | 50 | 2018 |
